Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genmab A/S : Partner Janssen Secures EU Approval for Darzalex SC Combo in Rare Organ Disease

06/22/2021 | 10:53am EDT


ę MT Newswires 2021
All news about GENMAB A/S
07/23PRESS RELEASE : Pfizer And BioNTech to Supply U.S. -2-
DJ
07/22GENMAB A/S : Major shareholder announcement for Genmab A/S
AQ
07/22JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX (daratumumab) for the..
AQ
07/21Major Shareholder Announcement
GL
07/21GENMAB A/S : receives royalties on worldwide net sales from Janssen Biotech, Inc..
PU
07/21GENMAB A/S : Says Darzalex Sales in Q2 Hit $1.43 Billion
MT
07/21PRESS RELEASE : Pfizer and BioNTech Announce -3-
DJ
07/21Genmab Announces Net Sales of DARZALEX« (daratumumab) for the Second Quarter ..
GL
07/21Genmab Announces Net Sales Results of Darzalex« (Daratumumab) for the Second ..
CI
07/19PRESS RELEASE : BioNTech to Acquire Kite's Neoantigen TCR Cell Therapy R&D Platf..
DJ
More news
Financials
Sales 2021 7 670 M 1 218 M 1 218 M
Net income 2021 2 131 M 338 M 338 M
Net cash 2021 15 048 M 2 390 M 2 390 M
P/E ratio 2021 92,4x
Yield 2021 -
Capitalization 183 B 29 074 M 29 085 M
EV / Sales 2021 21,9x
EV / Sales 2022 16,3x
Nbr of Employees 871
Free-Float 95,1%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 2 801,00 DKK
Average target price 2 481,91 DKK
Spread / Average Target -11,4%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S15.31%27 394
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308